Exciting news! Wave Neuroscience and Texas A&M Health just announced the second phase of their clinical trial using MeRT (Magnetic e-Resonance Therapy) to treat PTSD. This means we’re moving one step closer to FDA approval for MeRT in the treatment of Post-traumatic Stress Disorder.
Currently, the FDA has cleared the equipment used with the MeRT for the treatment of Depression and OCD. All other conditions are “off label.” That’s why the second phase of this trial is so vital.
Differences Between First and Second Phases
The first phase focused mainly on US military veterans who had experienced PTSD. These participants may have also had a Traumatic Brain Injury (TBI). This second phase opens the trial up to others who have experienced the debilitating effects of PTSD in their lives. Thus, the study will determine the effectiveness of MeRT for treating PTSD in a wide range of people. And if the person also has a TBI, they will receive MeRT for that as part of their treatment.
Kenneth Ramos, MD, PhD, executive director of Texas A&M Health Institute of Biosciences and Technology, is directing this phase of the trial. As Dr. Ramos said, “The results of the initial trial suggested that MeRT therapy may be effective for the treatment of post-traumatic stress disorder. This second phase of the investigation has been designed to further evaluate the efficacy and safety of MeRT in a larger and more diverse group of patients. Our goal is to find ways to improve the quality of life for patients afflicted with this devastating condition.”
Additionally, while the first phase of the trial involved 74 participants, this phase will enroll up to 175 people. The clinical trial will take place in Dallas, Texas, and San Diego, California, and will continue through the Spring of 2023.
We are excited to see the results of this trial and will keep you updated as it progresses.
To learn more about how we treat Post-traumatic stress disorder with MeRT, please visit our PTSD Treatment page.